Goldman Sachs cuts Waystar stock price target to $33 on guidance

Waystar reported Q1 2026 revenue and adjusted EBITDA about 1% and 5% above consensus, respectively, with 11% organic revenue growth and a 43% adjusted EBITDA margin. Goldman Sachs cut its price target to $33 from $38 but kept a Buy rating, citing sustained double-digit organic subscription growth and deleveraging progress. Management reiterated full-year 2026 guidance, and the stock trades at $25.27, down 23% YTD and 41% below its 52-week high.

Analysis

The setup is less about a one-quarter miss and more about the market re-rating the durability of Waystar’s organic growth after a clean post-acquisition integration. A sub-10x 2027 EV/EBITDA multiple implies the stock is still being valued like a decent software compounder, not a mission-critical healthcare workflow platform with recurring revenue and deleveraging optionality. The key second-order effect is that every incremental margin point now has more equity value because the balance sheet is likely past the most fragile phase of the acquisition cycle.

The weaker-than-usual beat matters because it can cap near-term multiple expansion, but it also lowers the bar for the next two quarters if management simply holds double-digit organic subscription growth. In this type of name, the real catalyst is not headline revenue—it is evidence that retention and pricing power remain intact while integration synergies convert into free cash flow. If that happens, the market tends to reward the business with a higher rule-of-40 style premium, especially once leverage continues drifting down.

The consensus may be underappreciating how much of the downside is already discounted: the shares are closer to a de-risked integration story than a broken growth story. The main risk is not a catastrophic fundamental miss, but a prolonged period of merely-good execution that keeps the stock trapped in a low-multiple range while investors wait for a cleaner acceleration signal. That makes the next 1-2 earnings prints the critical window; if growth stabilizes and margin holds, the stock can re-rate quickly, but if subscription growth decelerates below low-double digits, the market will likely keep valuing it as a cash-yield story rather than a compounder.

Key Decisions for Investors

• Initiate a starter long in WAY over the next 1-2 weeks, sized for a 3-6 month hold; use current levels as a base and add on any post-earnings weakness near the low-$20s. Target a move toward the high-$20s/low-$30s as deleveraging and FCF visibility improve; cut if organic subscription growth falls below 10%.
• Buy WAY January 2027 30 calls and finance with near-term upside call spreads if liquidity allows; this captures a multiple re-rating without overpaying for short-dated noise. Risk/reward is attractive if the stock re-rates from sub-10x 2027 EBITDA toward a more typical software-healthcare premium.
• Pair long WAY against a basket of slower-growing healthcare IT/software names with similar margin profiles but weaker organic growth durability. The trade should work over 2-4 quarters if Waystar continues to compound while peers remain stuck in low-growth, lower-multiple territory.
• For existing holders, sell a portion of upside via covered calls against the 30-35 strike over the next earnings cycle. This monetizes the near-term “good but not great” setup while preserving most of the upside if the market only gradually rewards execution.
• Avoid chasing here if the stock pops sharply on no new information; the better entry is on any consolidation after the next print. The downside is limited by valuation support, but the stock likely needs a second confirming quarter before a sustained re-rating is justified.